Mirum Pharmaceuticals (NASDAQ:MIRM – Get Free Report)‘s stock had its “buy” rating restated by HC Wainwright in a report issued on Wednesday,Benzinga reports. They presently have a $66.00 price target on the stock. HC Wainwright’s price objective would suggest a potential upside of 49.63% from the stock’s current price.
MIRM has been the subject of a number of other research reports. Evercore ISI boosted their target price on shares of Mirum Pharmaceuticals from $62.00 to $66.00 and gave the company an “outperform” rating in a research report on Thursday, August 8th. Citigroup lifted their price objective on shares of Mirum Pharmaceuticals from $65.00 to $68.00 and gave the stock a “buy” rating in a research report on Wednesday. Cantor Fitzgerald upped their price objective on Mirum Pharmaceuticals from $50.00 to $60.00 and gave the stock an “overweight” rating in a report on Thursday, August 8th. Robert W. Baird raised their target price on shares of Mirum Pharmaceuticals from $44.00 to $50.00 and gave the stock an “outperform” rating in a research report on Wednesday. Finally, Leerink Partners lifted their price target on shares of Mirum Pharmaceuticals from $47.00 to $49.00 and gave the stock an “outperform” rating in a research note on Thursday, October 17th. Ten investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, Mirum Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $57.73.
View Our Latest Analysis on MIRM
Mirum Pharmaceuticals Stock Performance
Mirum Pharmaceuticals (NASDAQ:MIRM – Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.15. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 40.98%. The firm had revenue of $90.38 million for the quarter, compared to the consensus estimate of $81.99 million. During the same quarter in the previous year, the company earned ($0.57) earnings per share. The business’s revenue was up 89.4% compared to the same quarter last year. On average, research analysts forecast that Mirum Pharmaceuticals will post -1.84 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several large investors have recently added to or reduced their stakes in the company. Quest Partners LLC raised its position in shares of Mirum Pharmaceuticals by 7,513.3% in the 2nd quarter. Quest Partners LLC now owns 1,142 shares of the company’s stock worth $39,000 after buying an additional 1,127 shares during the period. Amalgamated Bank increased its holdings in shares of Mirum Pharmaceuticals by 60.8% during the second quarter. Amalgamated Bank now owns 1,357 shares of the company’s stock valued at $46,000 after purchasing an additional 513 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Mirum Pharmaceuticals by 22.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,725 shares of the company’s stock worth $67,000 after buying an additional 318 shares in the last quarter. ProShare Advisors LLC bought a new position in shares of Mirum Pharmaceuticals during the 2nd quarter valued at about $213,000. Finally, Creative Planning acquired a new position in shares of Mirum Pharmaceuticals in the 3rd quarter valued at $249,000.
Mirum Pharmaceuticals Company Profile
Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.
Read More
- Five stocks we like better than Mirum Pharmaceuticals
- Election Stocks: How Elections Affect the Stock Market
- Rocket Lab is the Right Stock for the Right Time
- What Are the U.K. Market Holidays? How to Invest and Trade
- SoundHound AI Will Advance By Triple Digits in 2025: Here’s Why
- 5 discounted opportunities for dividend growth investors
- Celsius Holdings: Big Drop, Big Opportunity? Analysts Say Yes
Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.